Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor

Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists

(2020) Uta Schilling et al.   CLINICAL PHARMACOKINETICS

Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development

(2020) Rocco P. Milluzzo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction

(2020) Peter Sinnaeve et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Selatogrel for Acute Myocardial Infarction

(2020) Johanne Silvain et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes

(2019) Robert F Storey et al.   EUROPEAN HEART JOURNAL

Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease

(2018) Francesco Franchi et al.   CIRCULATION

2018 ESC/EACTS Guidelines on myocardial revascularization

(2018) Franz-Josef Neumann et al.   EUROPEAN HEART JOURNAL

Clinical Pharmacology of the Reversible and Potent P2Y12 Receptor Antagonist ACT-246475 After Single Subcutaneous Administration in Healthy Male Subjects

(2018) Pierre-Eric Juif et al.   JOURNAL OF CLINICAL PHARMACOLOGY

ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy

(2018) Davide Capodanno et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

(2017) Marco Valgimigli et al.   EUROPEAN HEART JOURNAL

In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y 12 Receptor–Mediated Signaling in Ticagrelor-Treated Patients

(2017) Fabiana Rollini et al.   JACC-Cardiovascular Interventions

Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Mohsen Naghavi et al.   LANCET

Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists

(2016) David J. Schneider   CORONARY ARTERY DISEASE

A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study

(2016) Fabiana Rollini et al.   EUROPEAN HEART JOURNAL

Pharmacodynamic effects during the transition between cangrelor and prasugrel

(2015) David J. Schneider et al.   CORONARY ARTERY DISEASE

Switching P2Y12-receptor inhibitors in patients with coronary artery disease

(2015) Fabiana Rollini et al.   Nature Reviews Cardiology

Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12receptorsin vitro

(2015) Heather M. Judge et al.   PLATELETS

A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial

(2014) Daniela Baldoni et al.   CLINICAL DRUG INVESTIGATION

Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor–Mediated Signaling in Prasugrel-Treated Patients

(2014) Fabiana Rollini et al.   JACC-Cardiovascular Interventions

Pharmacodynamic Effects During the Transition Between Cangrelor and Ticagrelor

(2014) David J. Schneider et al.   JACC-Cardiovascular Interventions

Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease

(2013) Dominick J. Angiolillo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects

(2012) Yi-min Cui et al.   ACTA PHARMACOLOGICA SINICA

ST-elevation myocardial infarction: Is there time for Q waves?

(2012) M. Mercuri et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease

(2012) Matthew J. Price et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A Comparison of the VerifyNow P2Y12 Point-of-Care Device and Light Transmission Aggregometry to Monitor Platelet Function with Prasugrel and Clopidogrel: An Integrated Analysis

(2010) Joseph A Jakubowski et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

(2009) Christoph Varenhorst et al.   AMERICAN HEART JOURNAL

Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans

(2009) Nagy A. Farid et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist

(2009) Wendell S. Akers et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects

(2009) Ying G. Li et al.   PLATELETS

The reversible P2Y12antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

(2008) N. L. DOVLATOVA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect

(2007) Steven R. Steinhubl et al.   THROMBOSIS RESEARCH